(MedPage Today) — CHICAGO — Transcatheter aortic valve replacement (TAVR) continued to hold its own against surgery for younger patients at low surgical risk, with the Evolut Low Risk trial now halfway to its goal of 10-year follow-up.
In…
Source link : https://www.medpagetoday.com/meetingcoverage/acc/114889
Author :
Publish date : 2025-03-30 19:46:00
Copyright for syndicated content belongs to the linked Source.
